NCT05626842 is a NA clinical trial of Total Diet Replacement (800kcal/day) in Type 2 Diabetes, sponsored by Oviva UK Ltd.

Who is sponsoring NCT05626842?

NCT05626842 is sponsored by Oviva UK Ltd.

What drugs are being tested in NCT05626842?

Interventions in NCT05626842: Total Diet Replacement (800kcal/day).

What condition does NCT05626842 study?

NCT05626842 studies Type 2 Diabetes.

Is NCT05626842 still recruiting?

NCT05626842 is currently status unknown. Last updated 25 November 2022.

Last reviewed 2022-11-25 · How we verify

NCT05626842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The DR-EAM Type 2 Diabetes Study

Status unknown NA Last updated 25 November 2022

What this trial tests

NA trial testing Total Diet Replacement (800kcal/day) in Type 2 Diabetes in 197 participants. Status unknown.

Timeline

20 January 2021

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Oviva UK Ltd
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	197
Start date	20 January 2021
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Total Diet Replacement (800kcal/day)

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Oviva UK Ltd

Who can join

Adults 18 to 65, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this 12-month interventional study is to analyse the clinical outcome benefits, scalability and cost-effectiveness of a digital Low-Calorie digital Type 2 diabetes mellitus (T2DM) remission program compared to usual National Health System (NHS) care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Oviva UK Ltd trials

Trials by the same sponsor.

NCT06119204 — SAFE-LCD Trial, for Insulin-treated Adults Living With Type 2 Diabetes · NA · terminated
NCT05648903 — The Transform Type 2 Diabetes Study · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05626842 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oviva UK Ltd
Last refreshed: 25 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05626842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing